Methylphenidate transdermal system: clinical applications for attention-deficit/hyperactivity disorder
Josephine Elia1, Zoe Wilson, Lilly Sehgal La Porta
1The Children's Hospital of Philadelphia, Science Center 3440 Market Street, Suite 200, Philadelphia, PA 19104, USA. elia@email.chop.edu
Expert Review of Clinical Pharmacology
|November 26, 2011
Summary
The methylphenidate transdermal system (MTS) offers improved adherence for attention-deficit/hyperactivity disorder (ADHD) treatment. This novel patch bypasses oral intake, enhancing methylphenidate delivery and efficacy.
Area of Science:
- Pharmacology
- Neuroscience
- Pediatrics
Background:
- Attention-deficit/hyperactivity disorder (ADHD) is a common neurodevelopmental disorder.
- Methylphenidate is a widely prescribed stimulant medication for ADHD.
- Current ADHD treatments primarily involve oral administration, which can affect adherence and absorption.
Purpose of the Study:
- To review the data on the methylphenidate transdermal system (MTS).
- To evaluate the efficacy and tolerability of MTS compared to existing ADHD treatments.
- To highlight the benefits of a novel, non-oral delivery system for methylphenidate.
Main Methods:
- Review of preclinical, clinical, and post-marketing studies on MTS.
- Comparative analysis of MTS efficacy and tolerability against other ADHD medications.
- Assessment of adherence and pharmacokinetic profiles associated with MTS.
Main Results:
- MTS demonstrates improved patient adherence due to once-daily patch application.
- The transdermal system bypasses gastrointestinal absorption and first-pass metabolism.
- Initial data suggest comparable efficacy and a manageable side effect profile for MTS.
Conclusions:
- The methylphenidate transdermal system (MTS) presents a significant advancement in ADHD pharmacotherapy.
- MTS offers a valuable alternative for patients seeking non-oral methylphenidate administration.
- Further research and post-marketing surveillance will continue to define the role of MTS in ADHD management.
More Related Videos
Related Concept Videos
01:30Attention-Deficit/Hyperactivity Disorder
Attention-deficit/hyperactivity disorder (ADHD) is a neurodevelopmental disorder characterized by persistent inattention, hyperactivity, and impulsivity. It affects approximately 5-8% of children globally, with around 60-70% of cases persisting into adulthood. ADHD has significant implications for educational attainment, social interactions, and occupational success.
Diagnostic Criteria and Symptoms
To diagnose ADHD, symptoms must manifest before age 12 and be evident across multiple settings.
Diagnostic Criteria and Symptoms
To diagnose ADHD, symptoms must manifest before age 12 and be evident across multiple settings.
01:18Transdermal Drug Delivery Systems
Transdermal drug delivery systems (TDDS) enable the controlled release of drugs across the skin into systemic circulation. They are particularly advantageous for drugs with short half-lives or narrow therapeutic indices, as they maintain consistent plasma concentrations and reduce the risk of subtherapeutic or toxic levels.TDDS are categorized into monolithic, reservoir, and mixed systems. Monolithic systems embed the drug in a polymer matrix, where diffusion governs release. Reservoir systems...
01:26Oral Drug Delivery Systems: Continuous-Release Systems
Continuous-release drug delivery systems offer a strategic approach to maintaining therapeutic drug levels over extended periods following oral administration. By modulating the release rate of active pharmaceutical ingredients, these systems minimize fluctuations in plasma concentrations, which enhances clinical efficacy and reduces the need for frequent dosing. Such characteristics make them particularly advantageous in managing chronic diseases where patient adherence and stable drug...
01:28Adrenergic Agonists: Mixed-Action Agents
Mixed-action adrenergic agonists, like ephedrine and pseudoephedrine, directly and indirectly affect adrenergic receptors. These agents stimulate adrenoceptors and indirectly release stored neurotransmitters, amplifying the adrenergic response.
Ephedrine and pseudoephedrine lack a catecholamine group, making them less susceptible to degradation by metabolic enzymes. They have increased oral bioavailability and lipophilicity, resulting in a longer duration of action. Their response is reduced by...
Ephedrine and pseudoephedrine lack a catecholamine group, making them less susceptible to degradation by metabolic enzymes. They have increased oral bioavailability and lipophilicity, resulting in a longer duration of action. Their response is reduced by...
01:24CNS Stimulants: Cocaine, Amphetamines and Cannabinoids
CNS stimulants, such as cocaine, amphetamines, and cannabinoids, have varying structures and mechanisms of action that lead to different therapeutic effects and side effects. Cocaine, with its molecular formula C17H21NO4, is a tropane alkaloid and a tertiary amino compound. It has two chemical forms: the hydrochloride salt and the "freebase." The former is in powder form, while the latter involves removing the hydrochloride salt to create a form that can be smoked. Cocaine exerts its effects by...
01:24Modified-Release Drug Delivery Systems: Site-Targeted
Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.